

Inspiring and facilitating best transfusion practices in Ontario.

# SOLVENT DETERGENT PLASMA: IS THIS WASHED PLASMA OR ...

Donna Berta RN, BScN Clinical Project Coordinator – Nursing Ontario Regional Blood Coordinating Network (ORBCoN)

November 22, 2023

### **Speaker Disclosure**

- No commercial product conflicts of interest to declare.
- Transfusion Transmitted Injuries Surveillance System, member Education Committee.
- Using Blood Wisely initiative, member nursing education development.
- Canadian Society of Transfusion Medicine, member Standards Committee.

# **Pre Transfusion Knowledge Question 1**

The transition to pathogen-reduced plasma (solvent detergent [S/D] plasma, Octaplasma<sup>™</sup>) provides an additional layer of safety to Canada's blood supply system.

The additional safety includes

- a) Decreased risk of allergic transfusion reactions.
- b) Inactivating <u>all</u> viruses.
- c) Inactivating <u>all</u> bacteria.
- d) Pooled product, patient/recipient blood group not relevant.

### **Pre Transfusion Knowledge Question 2**

Emma is a 23-year-old female trauma patient in your emergency department. Massive hemorrhage protocol is ordered. Blood group & screen test results are pending.

Select the plasma (S/D plasma) blood group to be transfused:

- a) Group O, Rh positive.
- b) Group O, Rh negative.
- c) Group AB, Rh negative.
- d) Group AB (Rh is not relevant for plasma transfusion).

# **Pre Transfusion Knowledge Question 3**

### When transfusing S/D plasma:

- a) Visual inspection of the product is not necessary; some visible particulates or clumping is okay.
- b) Compatible with all IV fluids (0.9% sodium chloride (NaCI), 5% dextrose in water (D5W), Ringer's Lactate).
- c) Use standard blood tubing with a 170 to 260 micron filter.
- d) Infuse as quickly as possible (half-life of coagulation proteins is less than 30 minutes).

### Transfusion in Ontario (April 1, 2022 to March 31, 2023)

(per ORBCoN annual hospital site visit template)

	N transfused / fiscal year	N transfused / day (approximate)
Red Blood Cells	347,752 units	953 units
Platelets	58,524 doses	160 doses
Plasma Components (excludes cryoprecipitate and S/D plasma)	39,611 units	109 units

### Learning Objectives:

After this session participants will be able to:

- Understand the unique features of Solvent Detergent (S/D) plasma & its clinical indications.
- Define nursing actions to safely administer S/D plasma (dose, compatibility, checking, tubing & filter, infusion rate, patient monitoring, possible adverse reactions).

NOTE: This presentation provides evidence informed information and is also based on interpretation of TM Standards and Best Practice. Refer to <u>your hospital policies and procedures</u> to guide your day-today practice.

### Outline:

- What is plasma?
- What is different about S/D plasma?
- Why is use of S/D plasma increasing now?

FP and S/D plasma

- Clinical Indications / Transfusion Guidelines.
- Dose.
- Compatibility.
- Administration checks.
- Tubing / filter, IV fluid and devices.
- Infusion rate.
- Patient monitoring.
- Possible adverse reactions.

### Outline:

- What is plasma?
- What is different about S/D plasma?
- Why is use of S/D plasma increasing now?

FP and S/D plasma

- Clinical Indications / Transfusion Guidelines.
- Dose.
- Compatibility.
- Administration checks.
- Tubing / filter, IV fluid and devices.
- Infusion rate.
- Patient monitoring.
- Possible adverse reactions.



#### <u>Plasma</u>

- Liquid part of blood, contains various types of proteins, including coagulation proteins necessary for the <u>clotting process</u> to stop bleeding.
- Stored frozen (preserves levels of certain coagulation proteins).
- Frozen plasma (FP) is produced from whole blood donation (frozen within 24 hours of collection).
- Apheresis frozen plasma (AFP) is produced via apheresis technology donation (frozen within 8 hours of collection).
- FP & AFP have similar levels of all non-labile coagulation factors (type of anticoagulant is indicated on the label).
- 1 unit mean volume: FP 289 mL; AFP 249 mL.

# What is different about S/D plasma?

### <u>S/D plasma (Octaplasma™)</u>

- Produced from large pools of plasma [many (630 1520) individual donations of the same ABO blood group]. Each bag is labelled with its specific ABO blood group.
- Undergoes pathogen reduction: treated with solvent detergent agents, then these agents are removed, followed by sterile filtration (Lipid-enveloped viruses inactivated; leukocytes depleted; prions removed).
- "Pool" is divided into 200 mL individual units (45 70 mg/mL human plasma proteins). All S/D plasma units have a uniform volume of 200 mL.
- All clotting factors levels are similar to FP, except for lower protein S and anti-plasmin levels.
- Pooling dilutes antibodies, allergens, and cytokines; decreases risk of allergic reactions, transfusion related acute lung injury (TRALI).
- FP & S/D plasma clinical indications are the same. There are some differences in the products, leading to significant change in hospital transfusion practice (in TML and for transfusionists).

# Why is use of S/D plasma increasing now?

- July 2022, Canadian Blood Services (CBS): plan to transition to pathogen-reduced platelet & plasma components as an additional layer of safety to the blood supply system in Canada (in addition to donor screening and testing of each blood donation).
- S/D plasma has been used in Canada since 2011 for select patients (undergoing plasmapheresis treatment and significant pulmonary comorbidities or allergic reactions to FP).
   S/D plasma has been widely used in Europe for several decades (primary plasma product in some countries).

#### **CBS Pathogen-Reduced Plasma Plan:**

- Phase 1: transition from FP to S/D plasma target of 80% of all transfused plasma to be S/D plasma by September 2023.
- Phase 2: (2024-25) replace the remaining 20% of FP with pathogenreduced frozen plasma using the same technology (Intercept Blood System) currently used to produce pathogen-reduced platelets.



### S/D plasma





FP & S/D plasma clinical indications are the same.

There are some differences in the products, leading to significant change in hospital transfusion practice (in TML and for transfusionists).

### **Outline:**

- What is plasma?
- What is different about S/D plasma?
- Why is use of S/D plasma increasing now?

### FP and S/D plasma

- Clinical Indications / Transfusion Guidelines.
- Dose.
- Compatibility.
- Administration checks.
- Tubing / filter, IV fluid and devices.
- Infusion rate.
- Patient monitoring.
- Possible adverse reactions.

# Patient Case 1, Question 1

Flo, a 69-year-old female underwent complex cardiac surgery (coronary artery bypass grafting, aortic valve replacement) 48 hours ago. In the OR, transfused: 8 units RBC, 4 units S/D plasma, 1 dose platelets.

Now, Flo is recovering well (extubated, on oxygen 1 LPM, vital signs stable, tolerating sips of clear fluids, minimal/scant chest tube drainage). Lab test results: Hb 78 g/L, platelets 88 X 10<sup>9</sup>/L, INR 1.5

Flo's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR.

Question 1: This is an appropriate **indication** for plasma transfusion. a) yes b) no

# FP & S/D plasma

### **Clinical Indications / Transfusion Guidelines (1)**

CBS Plasma Circular of Information; S/D plasma Octaplasma<sup>™</sup> Product Monograph; Bloody Easy 5.1; National Advisory Committee on Blood and Blood Products (NAC)

- Bleeding or prior to a significant operative/invasive procedure in patients with INR ≥ 1.8 due to multiple factor deficiency when no coagulation factor concentrate, or other alternative therapy is available or is contraindicated.
- Microvascular bleeding or massive hemorrhage protocol (MHP) activated, and patient clinical status precludes waiting for INR/PTT test results.
- Patients with thrombotic thrombocytopenia purpura (TTP).
- Preparation of reconstituted whole blood.
- Replacement fluid for therapeutic plasmapheresis procedures.

### NOTES:

 In the scenario of abnormal coagulation test results, to determine if plasma is indicated, the cause of the elevation must be determined (i.e., liver disease vs. warfarin effect vs. single factor deficiency).

# FP & S/D plasma Clinical Indications / Transfusion Guidelines (2)

### **NOTES continued:**

- Liver disease patients have preserved thrombin generation despite elevated INR levels; often do not need correction of the abnormality before procedures.
- Plasma should not be used to treat hypovolemia.
- Plasma is not indicated/required when INR < 1.8 (coagulation factor levels are adequate for hemostasis).
- Don't transfuse plasma if INR elevated but patient is not actively bleeding.
- Don't transfuse plasma for reversal of heparin, low molecular weight heparin, warfarin, direct oral anticoagulants.
- <u>S/D plasma:</u> may give at the same time as FP.
- <u>S/D plasma contraindication</u>: patients with severe protein S deficiency.
   S/D plasma has significantly lower levels of protein S as compared to FP, which may result in an increased risk of blood clots. If patients with severe protein S deficiency require plasma transfusion, they should receive FP.

# Patient Case 1, Question 2

Flo, a 69-year-old female underwent complex cardiac surgery (coronary artery bypass grafting, aortic valve replacement) 48 hours ago. In the OR, transfused: 8 units RBC, 4 units S/D plasma, 1 dose platelets.

Now, Flo is recovering well (extubated, on oxygen 1 LPM, vital signs stable, tolerating sips of clear fluids, minimal/scant chest tube drainage). Lab test results: Hb 78 g/L, platelets 88 X 10<sup>9</sup>/L, INR 1.5

Flo's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR. Note: Flo's weight: 70 kg

Question 2: This is an appropriate **dose** for plasma transfusion for Flo.

- a) yes
- b) no
- c) possibly

# FP & S/D plasma Dose (1)

#### **FP CBS Plasma Circular of Information**

- Depends on the clinical situation and patient size.
- Common dosing is 10 15 mL per kg body weight.

### S/D plasma Octaplasma<sup>™</sup> Product Monograph

- Depends upon the clinical situation and underlying disorder.
- Generally accepted starting dose 12 15 mL per kg body weight (this should increase plasma coagulation factor levels by about 25%).

#### **Historical Practice**

• Adults: Large - 4 units; Small - 3 units

\*\*\*Both FP and S/D plasma are available in TML in units.\*\*\*

# FP & S/D plasma Dose (2)

\*\*\*Follow hospital policy established by the transfusion medicine service.\*\*\*

#### Bloody Easy 5.1

- Indication MHP, minimum ratio 2:1 RBC:plasma units.
- Table with 5 kg weight increments, dosing in mL (10 15 mL/kg).

#### NAC October 2023

- Indication correction of abnormal coagulation tests.
- Provide suggestions/examples with logistical & pragmatic considerations (e.g., TML policy allowing for substitution of FP for S/D plasma (or vice versa) as needed due to inventory issues).
- Two example tables, first one 15-20 kg weight increments.
- Additional update pending (hopefully in December).

# FP & S/D plasma Dose (3)

#### NAC October 2023 Example dose range table S/D plasma & FP (mL & units).

- 1. Dose calculated using middle weight x 12.5 mL/kg.
- 2. Number of S/D plasma units calculated using a unit volume of 200 mL.
- 3. Number of FP units calculated assuming a mean unit volume of 289 mL.
- 4. For weights above 100 kg, the plasma dose is capped using 100 kg dose.
- 5. Dose for 10 mL/kg calculated using upper weight for each category.
- 6. Dose for 15 mL/kg calculated using lower weight for each category.

Weight (kg)	10 mL/kg⁵	15 mL/kg <sup>6</sup>	S/D plasma dose <sup>1,2</sup>	FP dose <sup>1,3</sup>
< 40 kg			12 mL/kg	12 mL/kg
40 - 44.9 kg	450 mL	600 mL	3 units	2 units
45 - 49.9 kg	500 mL	675 mL	3 units	2 units
50 - 54.9 kg	550 mL	750 mL	3 units	2-3 units
55 - 59.9 kg	600 mL	825 mL	3-4 units	3 units
60 - 64.9 kg	650 mL	900 mL	4 units	3 units
65 - 69.9 kg	700 mL	975 mL	4 units	3 units
70 - 74.9 kg	750 mL	1050 mL	4-5 units	3 units
75 - 79.9 kg	800 mL	1125 mL	4-5 units	3-4 units
80 - 84.9 kg	850 mL	1200 mL	5-6 units	4 units
85 - 89.9 kg	900 mL	1275 mL	5-6 units	4 units
90 - 94.9 kg	950 mL	1350 mL	5-6 units	4 units
95 - 99.9 kg	1000 mL	1425 mL	6 units	4-5 units
100+ kg <sup>4</sup>	1000 mL	1425 mL	6 units	4-5 units

#### www.transfusionontario.org



# FP & S/D plasma Neonate Notes & Pediatric Pearls

#### NAC

Neonates

• Based on limited data, there is no reason to expect differences in clinical efficacy with S/D Plasma as compared to FP.

Pediatrics

• Based on limited data, S/D Plasma and FP should be considered equally effective in pediatric patients and can be used interchangeably.

Bloody Easy 5.1

• Dose: 10-15 mL/kg including for pediatrics.

# Patient Case 1, Question 3

Flo, a 69-year-old female underwent complex cardiac surgery (coronary artery bypass grafting, aortic valve replacement) 48 hours ago. In the OR, transfused: 8 units RBC, 4 units S/D plasma, 1 dose platelets.

Now, Flo is recovering well (extubated, on oxygen 1 LPM, vital signs stable, tolerating sips of clear fluids, minimal/scant chest tube drainage). Lab test results: Hb 78 g/L, platelets 88 X 10<sup>9</sup>/L, INR 1.5

Flo's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR.

Question 3: Assess response to plasma clinically & by repeating INR 30-60 minutes post transfusion.

a) yes b) no

### Patient Case 2, Question 1

Note: This fictitious case is presented <u>solely to discuss administration of plasma</u> and does not necessarily reflect current treatment for patients with liver disease.

Freddy, a 59-year-old male with cirrhosis of the liver, is awaiting liver transplant. Unfortunately, he fell and has fractured his hip. He requires urgent hip surgery. Freddy's weight is 80 kg. Lab test results: INR 2.5

Freddy's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR.

Question 1: For the plasma transfusion, Freddy requires a blood group test. a) yes b) no

# FP & S/D plasma Compatibility

### Plasma Compatibility

- Patients should be transfused plasma that is ABO compatible with their own red blood cells (antigens).
- Anti-A and/or anti-B antibodies in transfused plasma can hemolyse the patient's RBCs, if the patient's RBCs have the corresponding antigen on their surface.
- Rh(D) blood group is not relevant for plasma transfusion (plasma is a non-cellular blood component [i.e., no antigens]).

Patient ABO/Rh(D)	Compatible Blood Group for Transfusion			
Blood Group	RBC	Platelets	Plasma	Cryoprecipitate
O Positive	O Rh(D) positive or negative	O preferred** Rh(D) positive or negative	O, A, B, AB	
O Negative	O Rh(D) negative*	O preferred** Rh(D) negative*	O, A, B, AB	
A Positive	A, O Rh(D) positive or negative	A preferred** Rh(D) positive or negative	A, AB	Any Group Note:
A Negative	A, O Rh(D) negative*	A preferred** Rh(D) negative*	A, AB	Very infrequently used component.
B Positive	B, O Rh(D) positive or negative	B preferred** Rh(D) positive or negative	B, AB	Cryoprecipitate is interchangeable with Fibrinogen
B Negative	B, O Rh(D) negative*	B preferred** Rh(D) negative*	B, AB	Concentrate for fibrinogen replacement.
AB Positive	AB, A, B, O Rh(D) positive or negative	AB preferred** Rh(D) positive or negative	AB	
AB Negative	AB, A, B, O Rh(D) negative*	AB preferred** Rh(D) negative*	AB	

**Compatibility Table** 

\* In urgent bleeding patient situations or during times of short supply, Rh(D) negative patients may need to receive Rh(D) positive RBC and platelets.

\*\* Platelets should be ABO compatible with patient's red blood cells (donor platelets are suspended in plasma). In urgent bleeding patient situations or during times of short supply, TML will follow established policies for ABO group substitution for platelets.

# Patient Case 2, Question 2

Note: This fictitious case is presented <u>solely to discuss administration of plasma</u> and does not necessarily reflect current treatment for patients with liver disease.

Freddy, a 59-year-old male with cirrhosis of the liver, is awaiting liver transplant. Unfortunately, he fell and has fractured his hip. He requires urgent hip surgery. Freddy's weight is 80 kg.

Lab test results: INR 2.5

Freddy's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR.

Freddy's ABO blood group result: O

Question 2: Freddy's first unit of plasma is still not ready (it has been almost 1 hour since his ABO blood group test result was posted). His nurse should call TML to find out what is taking so long.

- a) yes
- b) no
- c) possibly

# FP & S/D plasma Thawing plasma

	FP	S/D plasma
Shelf-life	12 months, frozen, at ≤ minus 18°C (approved, monitored freezer).	48 months, frozen, at ≤ minus 18°C (approved, monitored freezer).
Thawing (thawing system validated for this purpose, e.g., water bath; dry tempering system; multiple bags can be thawed in parallel in some thawing systems)	May take 20 - 30 minutes.	For not less than 30 minutes; should not be longer than 60 minutes. Allow to warm to approximately 37 °C before infusion.
Thawed Shelf-life	5 days (120 hours), at 1-6°C (approved, monitored refrigerator).	5 days (120 hours), at 2-8°C (approved, monitored refrigerator). Ideally, should be thawed shortly before use (within 1-2 hours). Pre-thawed, long-term-storage should be used only as an exception in cases where time plays a crucial role, e.g., MHP

### **Outline:**

- What is plasma?
- What is different about S/D plasma?
- Why is use of S/D plasma increasing now?

### FP and S/D plasma

- Clinical Indications / Transfusion Guidelines.
- Dose.
- Compatibility.
- Administration checks.
- Tubing / filter, IV fluid and devices.
- Infusion rate.
- Patient monitoring.
- Possible adverse reactions.

## Patient Case 2, Question 3

Note: This fictitious case is presented <u>solely to discuss administration of plasma</u> and does not necessarily reflect current treatment for patients with liver disease.

Freddy, a 59-year-old male with cirrhosis of the liver, is awaiting liver transplant. Unfortunately, he fell and has fractured his hip. He requires urgent hip surgery. Freddy's weight is 80 kg.

Lab test results: INR 2.5

Freddy's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR.

Freddy's ABO blood group result: O For Freddy, TML has issued S/D plasma, blood group O

Question 3: When checking the S/D plasma, the product lot number should be verified as identical and also recorded on Freddy's health record. a) yes b) no

# FP & S/D plasma Administration checks (1)

- Blood received from TML aligns with the order.
- Unequivocal (unmistakable) identification of the patient is mandatory.
- TM patient identifiers: surname, first name, unique identification number
- Patient must be wearing a patient identification armband.
- Patient identification information must remain attached to blood during transfusion.

For safety, at the bedside in the presence of the patient, follow 4 steps


- 1. Patient Identification (Order, Armband, Transfusion label, Chart label/issue form)
- 2. ABO Blood Group (Group & screen test result; Manufacturer label [FP: CBS; S/D plasma: Octapharma]; Transfusion label, Chart label/issue form)
- 3. Unit number (Manufacturer label [FP: CBS; S/D plasma: Octapharma]; Transfusion label; Chart label/issue form)
- 4. Expiry & Visual Inspection (Transfusion label; Chart label/issue form; Blood product)

#### S/D plasma Administration checks (2) Manufacturer S/D plasma label (per Octapharma, ISBT128 compliant) (0001 07 Blood group bar code Unit number, begins with "X" ctaplasma Solvent/Detergent (S/D) Unique to each S/D plasma unit Blood Group treated Human Plasma Plasma humain traité par Frozen / Congelé Solution for infusion / Solution pour perfusion Solvant/Détergent (S/D) Expiry date bar code 200 ml solution for parenteral administration by the intravenous route only. Groupe Sanga 200 ml de solution pour administration parentérale par voie intraveineuse uniquement (date of production One bag contains: Human plasma proteins 9.0 g-14.0 g. Sodium citrate dihydrate 0.88 g-1.48 g, Product name bar code Sodium dihydrogenphosphate dihydrate 0.06 g-0.24 g, Glycine 0.80 g-1.20 g. Octaplasma contains no + 48 months) preservative. Keep out of reach of children! Store in freezer in the dark at $\leq -18^{\circ}$ C. Do not use solutions that are cloudy or have deposits. After thawing, Octaplasma can be stored for up to 5 days at +2 to 8°C or for up to 8 hours at room temperature (+20 to 25°C) before use. Thaved product must not be refrozen. Unused product must be discarded. For dosage and use, see package insert. Follow instructions for use carefully. Pour la posologie et les instructions d'utilisation, voir la notice. Lire attentivement la notice avant utilisation, DIN: 02270013 Lot No .: / Expiry Date Manufactured for: Octapharma Canada Inc. DD/MM/YYYY AywwXzzz1 Toronto, ON M5L 1G1, Canad Octapharma lot number O octopiasma Blood Group 0, 200 ml octopiasma Blood Group 0, 200 ml Lot No: / Expiry Date: Manufactured by: Lot No: / Expiry Date: octapharma AYWWXZZZ1 AYWWXZZZ1 Octapharma Pharmazeutika Oberlaaerstr. 235, A-1100 Vienna, Austria DD/MM/YYYY DD/MM/YYYY Expiry date (date of production

+ 48 months)

#### S/D plasma Administration checks (3) Re-print thawed S/D plasma label (Hospital TML, ISBT128 compliant) UVENT DETER 200 mL St. Joseph's Healthoare Hamilton, ON LON 445 Blood group bar code Unit number, begins with "X" VOLUNTEER DONOR Unique to each S/D plasma unit XDiration Oats/Time 19 NOV 2023 08:4 NT DETERGENT Omu Product name bar code Expiry date/time bar code Hospital name & address FDA Registration number Expiry date/time date/time of thawing + 5 days (120 hours)

#### S/D plasma **Administration checks (4) Transfusion Label (Hospital TML)** Surname, first name PATIENT NAME PATIENT ABO/Rh **BLOODCOLUMN, TEST** O POS MEDICAL RECORD NUMBER LOCATION G9004245 Hospital Ward Patient blood group PRODUCT TYPE PRODUCT CODE Unique identification THWD SOLVENT DETERGENT X0008 PLASMA number UNIT NUMBER UNIT ABO/Rh X000223200234-C ο ROSSMATCH RESULT DATE / TIME / TECH Product name 15/11/23 12:38 MLT Assigned Unit blood group Hospital name & address Unit number, begins with "X" Independent double check required prior to starting the administration. DO NOT transfuse if there is a discrepancy. Unique to each S/D plasma unit



# S/D plasma Administration checks (4)

Expiry, "Complete transfusion by" (Hospital TML & Transfusionist)

	FP	S/D plasma
Complete Transfusion By	Within 4 hours of removal from storage.	Within 4 hours of spiking the bag AND Can be stored for up to 8 hours at room temperature (20-25°C) before use.

#### S/D Plasma

• Issue Time (removal from temperature-controlled environment); transfusionist needs to know issue time to ensure transfusion safety.

# S/D plasma Administration checks (4)

#### **Visual Inspection (Hospital TML & Transfusionist)**



#### S/D Plasma

Do not transfuse products that are cloudy, have visible particulates/ precipitates, clumping or have deposits.

#### Solvent Detergent (S/D) Plasma: Is this Washed Plasma or ...


#### **Outline:**

- What is plasma?
- What is different about S/D plasma?
- Why is use of S/D plasma increasing now?

#### FP and S/D plasma

- Clinical Indications / Transfusion Guidelines.
- Dose.
- Compatibility.
- Administration checks.
- Tubing / filter, IV fluid and devices.
- Infusion rate.
- Patient monitoring.
- Possible adverse reactions.

# FP & S/D plasma **Tubing / filter, IV fluid and devices**



Blood tubing / filter



Alaris or Baxter pump

Hotline blood

warmer

Pressure bag

**Devices** 

•

- Only those approved per Health Canada Medical Device Regulations.
- Use based on manufacturer's recommendations & • equipment quality control system (validated, calibrated, and maintained).

- Blood tubing / filter use for a maximum of 4 units of blood or 4 hours of time
- Can be given concurrently with FP or other blood products.
- IV fluid: 0.9 % NaCl (sodium chloride). ٠

Blood tubing with 170-260 micron filter.

- Prime tubing: 0.9 % NaCl or plasma •
  - IV setup: to stop abruptly & maintain IV access
    - 0.9% NaCl flush syringes + any IV fluid line or
    - 0.9% NaCl IV line

NO medications are compatible.



38

Level 1 rapid infuser

### Patient Case 2, Question 4

Note: This fictitious case is presented <u>solely to discuss administration of plasma</u> and does not necessarily reflect current treatment for patients with liver disease.

Freddy, a 59-year-old male with cirrhosis of the liver, is awaiting liver transplant. Unfortunately, he fell and has fractured his hip. He requires urgent hip surgery. Freddy's weight is 80 kg.

Lab test results: INR 2.5

Freddy's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR.

For Freddy, TML has issued S/D plasma, blood group O

Question 4: When transfusing each unit of S/D plasma, best practice is to infuse at 50 mL/hour, over 4 hours.

- a) yes
- b) no

# FP & S/D plasma Infusion rate (1)

If patient's clinical status permits (i.e., patient stable, not bleeding; transfusion not urgent) initiate transfusion cautiously and slowly.

• For the first 15 minutes,



<u>Adults</u> 50 mL/hour



<u>Neonate/Pediatric</u> 1 mL/kg/hour, up to 50 mL/hour

**Note:** If tubing/filter was primed with 0.9% NaCl, then re-prime tubing with plasma to ensure initial slow infusion rate is infusing plasma (Blood tubing volume: Alaris ≈ 33 mL; Baxter ≈ 15 mL)

- After 15 minutes, assess patient and re-check vital signs.
- If no signs/symptoms of transfusion reaction, increase to rate ordered.
- Administer plasma immediately prior to planned procedures.

## FP & S/D plasma Infusion rate (2)

#### FP

• over 30 -120 minutes; maximum is 4 hours from time of issue from TML.

#### S/D plasma

- Best practice as for FP.
- Product monograph maximum 1 mL/kg/minute (70 kg patient, 1 unit in 3 minutes)
- Plasmapheresis machine rates: 100 250 mL/minute
- Rapid infuser rates: 750 -1000 mL/minute
- Some discussions regarding rapid infusions (MHP), citrate anticoagulant in S/D plasma, potential for citrate toxicity (citrate binds calcium). Concentration of citrate in S/D plasma & FP are similar. In MHP scenarios, benefit of rapid infusion outweighs the potential risk for citrate toxicity (as well, giving added calcium is part of MHP).

**If TACO risk** (Transfusion Associated Circulatory Overload)

• prevention strategies (slower)

#### ATTENTION

Patients receiving plasma are at high risk for Transfusion-Associated Circulatory Overload (TACO)!

# FP & S/D plasma TACO

TACO (Transfusion Associated Circulatory Overload)

- Leading cause of transfusion related deaths; Prevention is imperative!
- Occurs secondary to transfusion at a rapid rate and/or the specific patient's cardiac capacity is unable to tolerate transfusion fluid volume.
- Signs: acute/worsening respiratory distress, decreased oxygen saturation, tachycardia, increased blood pressure, acute pulmonary edema.

#### **TACO Risk Factors**

- Advanced age
- History of heart failure
- History of myocardial infarction
- Left ventricular dysfunction
- Renal dysfunction
- Positive fluid balance
   If risk, review with prescriber
   for prevention strategies

#### **TACO Prevention Strategies**

- Transfuse only 1 unit at a time
- Transfuse slowly over longer time period (maximum 4 hours per unit)
- Pre-transfusion diuretic
   (PO 30 minutes prior; IV just prior)
- TML to divide unit (if equipment available, then transfuse each part over maximum 4 hours)

### Patient Case 2, Question 5

Note: This fictitious case is presented <u>solely to discuss administration of plasma</u> and does not necessarily reflect current treatment for patients with liver disease.

Freddy, a 59-year-old male with cirrhosis of the liver, is awaiting liver transplant. Unfortunately, he fell and has fractured his hip. He requires urgent hip surgery. Freddy's weight is 80 kg.

Lab test results: INR 2.5

Freddy's physician orders: Transfuse 4 units plasma, each unit over 1 hour. Thirty minutes post transfusion, recheck INR.

Freddy has been transfused about 3 <sup>1</sup>/<sub>2</sub> units of S/D plasma. His wife notes he is now quite short of breath. Freddy's nurse comes to assess.


Question 5: **Immediately**, Freddy's nurse should check his vital signs and call his physician.

a) yes b) no

### FP & S/D plasma Possible adverse reactions

- If a possible acute transfusion reaction is suspected:
  - Stop Stop the transfusion
  - Maintain IV access
  - Check vital signs
  - o Verify patient armband identification matches with transfusion label
  - Notify prescriber
  - Patient care as per order
  - Report reaction to TML
  - o Document all details
- All unexpected, unusual or serious symptom(s) must be identified, managed and reported to TML for investigation.
- TML must report certain reactions to the Manufacturer/CBS/Health Canada.

#### FP & S/D plasma Acute Reaction Chart (1)



This document is intended for information purposes only. Hospitals may find this document provides guidance to be modified to align with their facility's polices and procedures.

Version 4.0 October 2020 Refer to TTISS website https://ttiss.mcmaster.ca/ select Resources tab

#### FP & S/D plasma Acute Reaction Chart (2)

SIGNS & SYMPTOMS		TIMING	POSSIBLE ETIOLOGY	RECOMMENDED INVESTIGATIONS	SUGGESTED TREATMENT AND ACTIONS	
DYSPNEA or SpO <sub>2</sub> (oxygen saturation) of 90% or less and a decrease of at least 5 % from pre-transfusion or intervention required to maintain SpO <sub>2</sub> (oxygen saturation)	With Hypertension, tachycardia, +/- FEVER	During or up to 12 hours post transfusion	TACO* (Transfusion Associated Circulatory Overload)	TML: Group & Screen, DAT     Consider chest x-ray:     Findings - pulmonary edema, Kerley B lines,     peri bronchial cuffing; may be pleural fluid     Cardiac biomarkers (as available)	DO NOT restart transfusion           Oxygen, high fowler's position, diuretics (document fluid balance)           Future transfusion;           Slow transfusion rate           Pre-transfusion diuretics **           Consider TML to divide unit (as available)	
	ACUTE DYSPNEA With HYPOTENSION, tachycardia, +/- FEVER	During or up to 6 hours post transfusion	TRALI (Transfusion Related Acute Lung Injury)	TML: Group & Screen, DAT     TML: Group & Screen, DAT     Alveolar infiltrates without elevated     pulmonary pressures     If also hypoxia: blood gases     Canadian Blood Services requires follow up     information & patient blood tests, contact     TML, will assist in sending samples	DO NOT restart transfusion Support; vasopressors (benefit uncertain for diuretics (document fluid balance), steroids, and bronchodilators) Serious reaction, call TML immediately	
	With FEVER +/- HYPOTENSION	Possible Etiology: Bacterial contamination, Acute hemolytic transfusion reaction Consider/Follow FEVER, <u>High Risk</u> : Timing, Recommended Investigations, Suggested Treatment and Actions				
	With URTICARIA, Airway or Facial Edema, HYPOTENSION	Possible Etiology: Anaphylactoid Reaction / Anaphylaxis Consider/Follow URTICARIA, With other symptoms: Timing, Recommended Investigations, Suggested Treatment and Actions				
	Mild respiratory symptoms that do not align with TACO or TRALI	During or up to 24 hours post transfusion	TAD (Transfusion Associated Dyspnea)	<ul> <li>Consider chest x-ray: Findings - normal/unchanged, no pulmonary edema, No bilateral interstitial/alveolar infiltrates</li> </ul>	DO NOT restart transfusion <ul> <li>Supportive care per physician's discretion: oxygen, respiratory support</li> </ul>	
HYPOTENSION 5BP (Systolic blood pressure) 30 mmHg or lower	Alone or with facial flushing	During or up to 4 hours post transfusion	***Bradykinin mediated hypotension	No testing required	DO NOT restart transfusion     Supportive care per physician's discretion: IV fluids     If taking ACE (angiotensin converting enzyme) inhibitor     medication, consider an alternative anti-hypertensive agent     prior to additional transfusion	
AND from pre-transfusion SBP: 30 mmHg or greater	With FEVER, +/- DYSPNEA	Possible Etiology: Bacterial contamination, Acute hemolytic transfusion reaction Consider/Follow FEVER, <u>High Risk:</u> Timing, Recommended Investigations, Suggested Treatment and Actions				
absolute decrease	With URTICARIA, Airway or Facial Edema, DYSPNEA	Possible Etiology: Anaphylactoid Reaction / Anaphylaxis Consider/Follow URTICARIA, With other symptoms: Timing, Recommended Investigations, Suggested Treatment and Actions				
15 to 25 % or greater relative decrease      for     intervention required to     maintain SBP	With ACUTE DYSPNEA, tachycardia +/- FEVER	Possible Etiology: TRALI Consider/Follow ACUTE DYSPNEA: Timing, Recommended Investigations, Suggested Treatment and Actions				
	diuretics: Furosemide I	PO: onset 30 to 60 n	ninutes, maximal effect 1-2 h	failure, history myocardial infarction, left ventricular o ours, effect persists about 6-8 hours Is, effect persists about 2 hours	dysfunction, renal dysfunction, positive fluid balance	
Bradykinin is believ				ngiotensin converting enzyme} inhibitor medication - ( m leading to decreased bradykinin degradation.	decreased bradykinin degradation related to	

Version 4.0 October 2020 Refer to TTISS website https://ttiss.mcmaster.ca/ select Resources tab

#### FP & S/D plasma Transfusion Checklist

Unequivocal (unmistakeable) identification of the patient is mandatory. Patient must be wearing a patient identification armband. Patient identification information must remain attached to the blood for the duration of the transfusion.						
PRE-TRANSFUSION	TRANSFUSION	POST-TRANSFUSION				
<ul> <li>Informed Consent</li> <li>Per policy/procedure, questions addressed</li> <li>Exception: emergent, life-threatening bleed</li> <li>Transfusion Order</li> <li>Indication supported: labs, signs, symptoms</li> <li>Complete, required information included</li> <li>Group &amp; Screen Testing</li> <li>Required for compatible blood components</li> <li>ABO, Rh(D) blood groups, antibody screen (clinically significant antibodies)</li> <li>Label tube of blood at patient's bedside</li> <li>Prepare the Patient</li> <li>Educate: symptoms indicative of reaction</li> <li>Assess for transfusion history and TACO risk factors; follow up if indicated</li> <li>Prepare the Equipment</li> <li>Dedicated, patent IV (peripheral or central)</li> <li>Compatible IV fluid (only 0.9 % NaCl [sodium chloride] for blood components)</li> <li>Blood components – tubing/filter (170-260 microns); change after 4 units or 4 hours</li> <li>Platelets – always NEW/FRESH tubing/filter</li> <li>Prime tubing/filter: blood or compatible IV fluid</li> <li>IV setup to stop abruptly &amp; maintain TKVO: 0.9% NaCl If ush syringes + any fluid IV line or 0.9% NaCl IV line</li> <li>Infusion Devices: if Health Canada approved</li> <li>Pick Up Blood from TML (Transfusion Medicine Lab)</li> <li>Patient identification (surname, first name, unique identification number) and order</li> </ul>	<ul> <li>Checking Blood Components/Blood Products         <ul> <li>Blood received matches transfusion order</li> <li>At bedside, in physical presence of patient</li> <li><u>1. Patient Identification</u>: surname, first name, unique identification number identical on armband, order, transfusion &amp; chart label/tag</li> <li><u>2. ABO, Rh(D) Blood Groups (only for Components): identical/compatible</u> on Group &amp; screen test, CBS (Canadian Blood Services) label, transfusion &amp; chart label/tag</li> <li><u>3. Unit (Components) / Lot (Products)</u> Number: identical on CBS label (Components) / Manufacturer label (Products), transfusion &amp; chart label/tag</li> <li><u>4. Visual Inspection &amp; Expiry</u> Components: no clots, usual colour, ports intact, expires 4 hours after issue from TML Products: packaging/seal intact, colour as per manufacturer, vials/glass bottles – once entered/spiked, expires after 4 hours</li> <li>Close monitoring/observation required</li> <li>Minimum: within 30 minutes of starting, 15 minutes after starting, upon completion</li> <li>Temp, BP, pulse, respiratory rate, oxygen saturation; if TACO risk - chest auscultation</li> <li>Infusion Rate (for each unit)</li> <li>S0 ml/hour for first 15 minutes; can be deferred if acute bleeding</li> <li>Re-check after 15 minutes, if no indication of reaction then increase to rate as ordered</li> <li>Possible Transfusion Reaction</li> <li>If any adverse/unexpected/serious symptoms, STOP transfusion; refer to TITSS Reaction Chart</li> </ul> </li> </ul>	<ul> <li>Completing the Transfusion         <ul> <li>Comply with expiry time specific for blood component/blood product                 Outside the expiry time, discard remainder</li> <li>Component tubing: flush with 0.9 % NaCl</li> <li>Products given IV: flush (tubing/IV site) with compatible IV fluid</li> <li>Some hospitals require returning the empty blood bag to TML                 Otherwise dispose of blood tubing/bags in biohazardous waste</li> <li>Re-assess patient and re-check vital signs:</li></ul></li></ul>				

# **Post Transfusion Knowledge Question 1**

The transition to pathogen-reduced plasma (solvent detergent [S/D] plasma, Octaplasma<sup>™</sup>) provides an additional layer of safety to Canada's blood supply system.

The additional safety includes

- a) Decreased risk of allergic transfusion reactions.
- b) Inactivating <u>all</u> viruses.
- c) Inactivating <u>all</u> bacteria.
- d) Pooled product, patient/recipient blood group not relevant.

### **Post Transfusion Knowledge Question 2**

Emma is a 23-year-old female trauma patient in your emergency department. Massive hemorrhage protocol is ordered. Blood group & screen test results are pending.

Select the plasma (S/D plasma) blood group to be transfused:

- a) Group O, Rh positive.
- b) Group O, Rh negative.
- c) Group AB, Rh negative.
- d) Group AB (Rh is not relevant for plasma transfusion).

## **Post Transfusion Knowledge Question 3**

#### When transfusing S/D plasma:

- a) Visual inspection of the product is not necessary; some visible particulates or clumping is okay.
- b) Compatible with all IV fluids (0.9% sodium chloride (NaCI), 5% dextrose in water (D5W), Ringer's Lactate).
- c) Use standard blood tubing with a 170 to 260 micron filter.
- d) Infuse as quickly as possible (half-life of coagulation proteins is less than 30 minutes).

#### **Acknowledgements**

The Ontario Regional Blood Coordinating Network (ORBCoN) gratefully acknowledges funding support provided by the Ontario Ministry of Health. The views expressed in this presentation are those of the authors and of ORBCoN and do not necessarily reflect those of the Ontario Ministry of Health or the Government of Ontario.

Many thanks to my ORBCoN and Transfusion Medicine family for their ongoing mentorship and support.

#### References

Black L, Selby R, Brnjac E, Lin Y, Elbaz C, James P, Moffat, K Sholzberg M. Bloody easy coagulation simplified. 2nd ed. Toronto: Ontario Regional Blood Coordinating Network. 2019 [cited 2023 Nov 13]. 47p. Available from:

https://transfusionontario.org/wp-content/uploads/2020/06/ORBCON-EN-BE Coagulation 02259.pdf

Callum JL, Pinkerton PH, Lin Y, Cope S, Karkouti K, Lieberman L, Pendergrast JM, Robitaille N, Tinmouth AT, Webert KE. Bloody easy 5.1 blood transfusions, blood alternatives and transfusion reactions a guide to transfusion medicine. 5th ed. Toronto: Ontario Regional Blood Coordinating Network; 2022 [revised 2023; cited 2023 Nov 13]. 145p. Available from:

https://transfusionontario.org/en/category/bloody-easy-e-tools-publications/bloody-easy-for-healthcare-professionals/

Canadian Blood Services (CBS). Circular of information [Internet]. Ottawa (CA); CBS; 2023 [cited 2023 Nov 13]. Available from: <a href="https://www.blood.ca/en/hospital-services/products/component-types/circular-information">https://www.blood.ca/en/hospital-services/products/component-types/circular-information</a>

Canadian Blood Services (CBS). FAQ: Solvent detergent (S/D) treated plasma (Octaplasma). Ottawa (CA); CBS; 2022 [cited 2023 Nov 13]. Available from: <a href="https://professionaleducation.blood.ca/en/transfusion/publications/solvent-detergent-sd-treated-plasma-octaplasma">https://professionaleducation.blood.ca/en/transfusion/publications/solvent-detergent-sd-treated-plasma-octaplasma</a>

Octapharma Our Products in Canada. Octaplasma<sup>™</sup> solvent detergent (S/D) treated human plasma product monograph [Internet]. Toronto (CA): Octapharma Canada Inc; 2005 Aug 11 [revised 2022 Oct 31; cited 2023 Nov 13]. Available from:

https://www.octapharma.ca/api/download/x/b5e3a19300/octaplasma\_pm\_en\_31\_oct\_2022.pdf

#### **References Cont'd**

Ontario Regional Blood Coordinating Network. Bloody easy blood administration. version 3. Toronto: Ontario Regional Blood Coordinating Network; 2020 [cited 2023 Nov 13]. 146p. Available from: <u>https://transfusionontario.org/en/category/bloody-easy-e-tools-publications/bloody-easy-blood-administration/</u>

Ontario Regional Blood Coordinating Network. Provincial massive hemorrhage toolkit [Internet]. Toronto ON; Ontario Regional Blood Coordinating Network; 2020 Jul [cited 2023 Nov 13]. Available from: <a href="https://transfusionontario.org/wp-content/uploads/2023/02/MHP\_Toolkit\_v2.pdf">https://transfusionontario.org/wp-content/uploads/2023/02/MHP\_Toolkit\_v2.pdf</a>

Ontario Transfusion Transmitted Injuries Surveillance System (TTISS-ON). Home page [Internet]. Hamilton (CA); TTISS-ON: 2020 [cited 2023 Nov 13]. Available from: <u>https://ttiss.mcmaster.ca/?page\_id=506</u>

Tinmouth A. National Advisory Committee on Blood and Blood Products. Guidelines & recommendations NAC recommendations for management of dual inventory of solvent-detergent plasma and frozen plasma [Internet]. Ottawa: National Advisory Committee on Blood and Blood Products; 2023 Oct 13 [cited 2023 Nov 13]. Available from: <a href="https://nacblood.ca/en/resource/nac-recommendations-management-dual-inventory-solvent-detergent-plasma-and-frozen-plasma">https://nacblood.ca/en/resource/nac-recommendations</a> and frozen plasma and frozen plasma and solvent-detergent-plasma-and-frozen-plasma

Tinmouth A, Morrison D, Quinn J, Pavenski K, Webert K, Lett R. National Advisory Committee on Blood and Blood Products. Guidelines & recommendations NAC recommendations for the use of solvent-detergent plasma in Canada [Internet]. Ottawa: National Advisory Committee on Blood and Blood Products; 2023 Mar 10 [updated 2023 Jul 20; cited 2023 Nov 13]. Available from: <a href="https://nacblood.ca/en/resource/nac-recommendations-use-solvent-detergent-plasma-canada">https://nacblood.ca/en/resource/nac-recommendations-use-solvent-detergent-plasma-canada</a>

#### Solvent Detergent (S/D) Plasma: Is this Washed Plasma or ...



#### Email: bertad@mcmaster.ca